SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC]

9891 reported adverse events

Drugs of this class: REMDESIVIR

These side effects are most commonly reported by patients taking drugs of the SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] class:

#	Side effect	Count
0	OFF LABEL USE	1446
1	ALANINE AMINOTRANSFERASE INCREASED	912
2	ASPARTATE AMINOTRANSFERASE INCREASED	607
3	DEATH	583
4	ACUTE KIDNEY INJURY	552
5	BRADYCARDIA	545
6	COVID-19	536
7	LIVER FUNCTION TEST INCREASED	412
8	RESPIRATORY FAILURE	374
9	DRUG INEFFECTIVE	367

See all common reactions for SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC]

Drugs of the SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	SARS-COV-2 VIRAEMIA	6	0.4286
1	CLINICAL TRIAL PARTICIPANT	21	0.3962
2	COVID-19 TREATMENT	22	0.3607
3	COINFECTION	6	0.1875
4	PARAVENOUS DRUG ADMINISTRATION	6	0.1875
5	CRYPTOCOCCAL MENINGOENCEPHALITIS	11	0.1667
6	RHINOCEREBRAL MUCORMYCOSIS	24	0.1311
7	SARS-COV-2 RNA INCREASED	4	0.1176
8	PNEUMONIA SERRATIA	3	0.1034
9	ORBITAL COMPARTMENT SYNDROME	3	0.1000

See all enriched reactions for SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC]